Abstract
Endocrine tumors are hormonally active benign or malignant neoplasms arising within endocrine organs or from specialized cells of the amine precursor uptake and decarboxylation (APUD) system that are increasing in incidence as a result of sensitive biochemical tests and high-resolution diagnostic imaging. Not unlike tumors of other systems, endocrine neoplasms are heterogenous with variable prognosis characterized by well-differentiated thyroid cancer with very favorable outcome, medullary thyroid cancer and neuroendocrine-type tumors with intermediate outcomes, and anaplastic thyroid, adrenocortical, and Merkel cell cancers with the poorest clinical outcomes. Medical imaging has become a key component in diagnosis and staging of endocrine malignancies; however, even with great advances in computed tomography and magnetic resonance imaging, detection of small primary tumors and metastases continues to be a challenge. Complimentary functional imaging targets tumor cellular processes that actively accumulate radiopharmaceuticals, allowing sensitive and highly specific oncological imaging. Surveillance of endocrine malignancies commonly combines functional imaging with tumor-specific laboratory biomarkers. Furthermore, functional imaging studies can predict efficacy of radionuclide or receptor-based therapies. The last decade has seen an increasing use of combined PET-CT and SPECT-CT scanners designed to create functional and anatomic maps with resultant incremental diagnostic capabilities. These technologies together with the development of novel PET and SPECT radiopharmaceuticals make patient-individualized functional imaging protocols possible, based on the histological grade, degree of differentiation, and genetic profile of their endocrine neoplasm.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AADC:
-
Aromatic amino acid decarboxylase
- ACC:
-
Adrenocortical carcinoma
- ACTH:
-
Adrenocorticotrophic hormone
- APUD:
-
Amine precursor uptake and decarboxylation
- ATC:
-
Anaplastic thyroid cancer
- C11-HED:
-
C11-hydroxyephedrine
- C11-HTP:
-
C11-5-hydroxy-L-tryptophan
- C11-MTO:
-
C11-metomidate
- CEA:
-
Carcino-embryonic antigen
- CT:
-
Computed tomography
- Ctn:
-
Calcitonin
- DMSA:
-
Dimercaptosuccinic acid
- DOTA:
-
1,4,7,10–tetraazacyclododecane–1,4,7,10–tetraacetic acid
- DOTATATE:
-
DOTA-Ty3-octreotide
- DOTANOC:
-
DOTA-NaI-octreotide
- F18-FDA:
-
F18-fluorodopamine
- FDG:
-
F18-fluoro-2-deoxy-D-glucose
- F-DOPA:
-
6-L-F18-fluorodihydroxyphenylalanine
- FTC:
-
Follicular thyroid cancer
- GH:
-
Growth hormone
- I-131:
-
Iodine-131
- keV:
-
Kilo electron volt
- LAT1:
-
Large neutral amino acid transporter
- MCC:
-
Merkel cell carcinoma
- MEN:
-
Multiple endocrine neoplasia
- MIBG:
-
Metaiodobenzylguanidine
- MIP:
-
Maximum intensity projection
- MRI:
-
Magnetic resonance imaging
- MTC:
-
Medullary thyroid cancer
- NB:
-
Neuroblastoma
- NETs:
-
Neuroendocrine tumors
- OR:
-
Odds ratio
- PET-CT:
-
Positron emission tomography-computed tomography
- PGL:
-
Paraganglioma
- PHEO:
-
Pheochromocytoma
- PRL:
-
Prolactin
- PTC:
-
Papillary thyroid cancer
- SDHB:
-
Succinate dehydrogenase-subunit B
- SPECT-CT:
-
Single-photon emission computed tomography-computed tomography
- SRS:
-
Somatostatin receptor scintigraphy
- SSTR:
-
Somatostatin receptors
- SUV:
-
Standardized uptake value
- Tc99m:
-
Metastable-technetium-99
- TSH:
-
Thyroid stimulating hormone
- VMAT:
-
Vesicular monoamine transporter
- WDTC:
-
Well-differentiated thyroid cancer
References
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.
Lyhne D, et al. Rising incidence of Merkel cell carcinoma. J Plast Surg Hand Surg. 2011;45:274–80.
Vinik AI, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713–34.
Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin Radiol. 2008;63:241–51.
Park HM. 123I: almost a designer radioiodine for thyroid scanning. J Nucl Med. 2002;43:77–8.
Pentlow KS, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557–62.
Caroli P, et al. Non-FDG PET in the practice of oncology. Indian J Cancer. 2010;47:120–5.
Naji M, et al. Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management. J Endocrinol Invest. 2010;33:54–60.
Koopmans KP, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71:199–213.
Minn H, et al. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50:1915–8.
Al-Nahhas A, et al. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res. 2007;27:4087–94.
Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:153–62, ix.
Shapiro B, et al. Clinical experience with 75Se selenomethylcholesterol adrenal imaging. Clin Endocrinol (Oxf). 1981;15:19–27.
Bergstrom M, et al. PET with [11C]-metomidate for the visualization of adrenocortical tumors and discrimination from other lesions. Clin Positron Imaging. 1999;2:339.
Jemal A, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
Wong KK, et al. Molecular imaging in the management of thyroid cancer. Q J Nucl Med Mol Imaging. 2011;55:541–59.
McDougall IR, Hay ID. ATA guidelines: do patients with stage I thyroid cancer benefit from (131)I? Thyroid. 2007;17:595–6; author reply 596–7.
Schmidt D, et al. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18–23.
Spanu A, et al. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50:184–90.
Wong KK, et al. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol. 2008;191:1785–94.
Wong KK, et al. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol. 2009;82:860–76.
Barwick T, et al. SPECT/CT using Iodine-123 in patients with differentiated thyroid cancer – additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010.
Grewal RK, et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51:1361–7.
Van Nostrand D, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879–83.
Phan HT, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:958–65.
Eschmann SM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760–7.
Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987;28:910–4.
Feine U, et al. 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin. 1995;34:127–34.
Frilling A, et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001;234:804–11.
Grunwald F, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547–52.
Dong MJ, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun. 2009;30:639–50.
Razfar A, et al. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2010;136:120–5.
Wang W, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–13.
Robbins RJ, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498–505.
Cohen MS, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130:941–6.
Shie P, et al. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30:742–8.
Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg. 2008;207:259–64.
Ma C, et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol. 2010;163:177–83.
Lowe VJ, et al. 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med. 2003;44:1402–6.
Pryma DA, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med. 2006;47:1260–6.
Plotkin M, et al. Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid. 2002;12:155–61.
Neff RL, et al. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:525–38, xi.
Bogsrud TV, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid. 2008;18:713–9.
Poisson T, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:2277–85.
Rufini V, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother. 2008;62:139–46.
Bozkurt MF, et al. Functional nuclear medicine imaging of medullary thyroid cancer. Nucl Med Commun. 2008;29:934–42.
Czepczynski R, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1635–45.
Groussin L, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009;94:1713–22.
Rubello D, et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol. 2008;34:581–6.
Wong KK, et al. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. Nucl Med Commun. 2012;33:679–88.
Szakall Jr S, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43:66–71.
Ong SC, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501–7.
Hoegerle S, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71.
Luster M, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527–33.
Marzola MC, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21.
Conry BG, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57.
Cook MI, et al. An unusual ectopic location of a parathyroid carcinoma arising within the thyroid gland. J Clin Endocrinol Metab. 2012;97:1829–33.
Evangelista L, et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol. 2011;2:348–54.
Gardner CJ, et al. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J Clin Endocrinol Metab. 2010;95:4844–5.
De Herder WW, Lamberts SW. Imaging of pituitary tumours. Baillieres Clin Endocrinol Metab. 1995;9:367–89.
Ahmed M, et al. ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary. 2000;3:105–12.
Ilkhchoui Y, et al. FDG-PET/CT findings of a metastatic pituitary tumor. Cancer Imaging. 2010;10:114–6.
Jeong SY, et al. Incidental pituitary uptake on whole-body 18F-FDG PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging. 2010;37:2334–43.
Hyun SH, et al. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011;52:547–50.
Bergstrom M, et al. Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl. Neurosurgery. 1992;30:855–61.
Moraes AB, et al. Utility of [(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors. Pituitary. 2009;12:380–3.
Xu H, et al. The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine. 2009;36:385–91.
Alzahrani AS, et al. The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing’s disease. Pituitary. 2009;12:309–14.
Roman S. Adrenocortical carcinoma. Curr Opin Oncol. 2006;18:36–42.
Becherer A, et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm. 2001;16:289–95.
Mackie GC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:2665–71.
Leboulleux S, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91:920–5.
Khan TS, et al. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30:403–10.
Kloos RT, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460–84.
Blake MA, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy – initial experience. Radiology. 2006;238:970–7.
Boland GW, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;194:131–4.
Brady MJ, et al. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology. 2009;250:523–30.
Tessonnier L, et al. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging. 2008;35:2018–25.
Wong KK, et al. Evaluation of incidentally discovered adrenal masses with PET and PET/CT. Eur J Radiol. 2012;81:441–50.
Wong KK, et al. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl Med Commun. 2011;32:764–81.
Bagheri B, et al. Characterization of the normal adrenal gland with 18F-FDG PET/CT. J Nucl Med. 2004;45:1340–3.
Choyke PL. ACR Appropriateness Criteria on incidentally discovered adrenal mass. J Am Coll Radiol. 2006;3:498–504.
Wong KK, et al. Contemporary nuclear medicine imaging of neuroendocrine tumours. Clin Radiol. 2012.
Krausz Y, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003;59:565–73.
Gabriel M, et al. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging. 2005;32:1440–51.
Wong KK, et al. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol. 2010;17:291–7.
Apostolova I, et al. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement. Ann Nucl Med. 2010;24:477–83.
Wong KK, et al. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors. Clin Nucl Med. 2011;36:25–31.
Adams S, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79–83.
Binderup T, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704–12.
Binderup T, et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.
Schiesser M, et al. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours. Br J Surg. 2010;97:691–7.
Koopmans KP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26:1489–95.
Ambrosini V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281–6.
Krausz Y, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37:57–62.
Kumar R, et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011;21:2408–16.
Ambrosini V, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.
Haug A, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765–70.
Campana D, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353–9.
Koukouraki S, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460–6.
Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol. 2008;35:S27–34.
Pacak K, et al. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004;25:568–80.
Havekes B, et al. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging. 2008;52:419–29.
Rozovsky K, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol. 2008;190:1085–90.
Meyer-Rochow GY, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17:392–400.
Muros MA, et al. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998;19:735–42.
Shulkin BL, et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35–41.
Taieb D, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50:711–7.
Imani F, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513–9.
Taieb D, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69:580–6.
Ilias I, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083–7.
Shulkin BL, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125–31.
Kroiss A, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.
Howman-Giles R, et al. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007;37:286–302.
Jacobson AF, et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010;95:2596–606.
Kushner BH, et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397–405.
Mc Dowell H, et al. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2009;52:552.
Melzer HI, et al. (1)(2)(3)I-MIBG scintigraphy/SPECT versus (1)(8)F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011;38:1648–58.
Sharp SE, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237–43.
Piccardo A, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–71.
Shulkin BL, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21.
Gains JE, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52:1041–7.
Concannon R, et al. The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol. 2010;62:76–84.
Peloschek P, et al. Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol. 2010;73:317–23.
Lu Y, et al. Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma. Clin Nucl Med. 2012;37:759–62.
Belhocine T, et al. Clinical added-value of 18FDG PET in neuroendocrine-Merkel cell carcinoma. Oncol Rep. 2006;16:347–52.
Siva S, et al. 18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience. J Nucl Med 2013;54:1223–1229.
Schmidt MC, et al. 68Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma. Int J Clin Exp Med. 2012;5:363–366.
Wong KK, et al. Nuclear Medicine Imaging of Endocrine Neoplasms. Nucl Med Commun. 2014;35:1–19.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wong, K.K., Kandathil, A., Rubello, D., Gross, M.D. (2014). Functional Oncological Imaging of the Endocrine System. In: Luna, A., Vilanova, J., Hygino Da Cruz Jr., L., Rossi, S. (eds) Functional Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40582-2_28
Download citation
DOI: https://doi.org/10.1007/978-3-642-40582-2_28
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40581-5
Online ISBN: 978-3-642-40582-2
eBook Packages: MedicineMedicine (R0)